Recent advances in targeting LRRK2 for Parkinson’s disease treatment
Abstract Parkinson’s disease (PD) is a neurodegenerative disease with severe movement problems. Current treatments mainly focus on symptom management by reducing dopaminergic pathways in the brain. Despite these therapies, ongoing disease progression undermines the effectiveness of prevalent approac...
Saved in:
| Main Authors: | Mahsa Karami, Pantea Majma Sanaye, Atousa Ghorbani, Roshanak Amirian, Pouya Goleij, Mehregan Babamohamadi, Zhila Izadi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-025-06354-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome
by: Michael T. Maloney, et al.
Published: (2025-08-01) -
LRRK2G2019S Gene Mutation Causes Skeletal Muscle Impairment in Animal Model of Parkinson's Disease
by: Yiying Hu, et al.
Published: (2024-12-01) -
Roles of LRRK2 and its orthologs in protecting against neurodegeneration and neurodevelopmental defects
by: An Phu Tran Nguyen, et al.
Published: (2025-04-01) -
Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson’s disease
by: Zachary Gaertner, et al.
Published: (2025-05-01) -
Frequency of the LRRK2 G2019S mutation in late-onset sporadic patients with Parkinson’s disease
by: Hsin Fen Chien, et al.
Published: (2014-05-01)